Epigral Reports Record ₹736 Cr Q4 Revenue, Fueled by Capacity Expansions

Epigral Ltd. announced its fourth-quarter FY26 financial results, revealing a record revenue of ₹736 crore. This marks a significant 17% increase compared to ₹631 crore in the same period last year, driven by strong demand and improved volume growth.

The company also proposed a final dividend of ₹5 per share for FY26. However, profit after tax for the quarter slightly decreased to ₹82 crore from ₹87 crore in Q4 FY25.

Full Year Performance

For the full fiscal year FY26, Epigral's revenue stood at ₹2,542 crore, a marginal 1% decline from FY25. The EBITDA margin for FY26 was 22%, down from 25% in the previous fiscal. This reduction was attributed to lower plant utilization and fluctuations in raw material prices.

Strategic Investments for Growth

Epigral, formerly known as Meghmani Finechem, continues its transformation into a specialty chemical producer. The company is making substantial investments, including ₹394 crore in FY26 capital expenditure, to expand capacities for key products like CPVC Resin and Epichlorohydrin (ECH). These projects are progressing well and are expected to commission by the first half of FY27.

Upon completion, these expansions aim to make Epigral the world's largest CPVC resin producer by capacity and India's leading ECH producer. A wind solar hybrid power plant is also being added to enhance the company's sustainable operations.

Market Outlook and Shareholder Returns

The strategic capacity expansions are designed to meet India's growing demand and support import substitution. The proposed final dividend reflects confidence in the company's near-term prospects and its commitment to shareholder returns.

However, the company's Chairman noted that momentum for FY27 might be influenced by global economic trends, suggesting potential market volatility.

Key Risks to Monitor

Investors should be aware of potential risks including the impact of global economic uncertainty on demand, volatility in raw material costs affecting margins, and the execution risk associated with completing large capital projects on time and within budget.

Competitive Landscape

In the CPVC resin market, Epigral faces competition from players like Astral Limited and Prince Pipes and Fittings Ltd, as well as domestic manufacturer DCW Limited. In the Epichlorohydrin sector, competitors include Vizag Chemical and High Mountain Chem, with DCM Shriram also planning to enter the market.

Looking Ahead

For FY25, Epigral reported revenues of ₹2,565 crore, with an EBITDA margin of 28% and ROCE of 25%. Key areas to track include the timely completion and ramp-up of new capacities, FY27 performance amid global economic shifts, dividend payouts, ongoing margin trends, and progress on sustainability initiatives.